CENTRAL PHARMACEUTICALS LIMITED

2-A/1, South-West Darus Salam Road (2nd Floor), Mirpur-1, Dhaka-1216
Phone :+88-02-7119404, 7119661, Fax: +88-02-9565992
E-mail: info@centralphl.com, Web:www.centralphl.com

FIRST QUARTER FINANCIAL STATEMENTS
(UN-AUDITED) as at 30 September, 2016

Dear Shareholders,
As per clause No. 17(1) of DSE (Listing) Regulation 2016, we are pleased to enclose the Financial Statements (un-audited) showing, Statement of Financial position, Statement of Comprehensive Income, Statement of Cash Flow and Statement of Changes in Equity for the First Quarter ended on Setember 30, 2016

Statement of Financial Position (Un-Audited) as at 30 September, 2016

Particulars	30-09-2016 Taka	30-06-2016 Taka
ASSETS		
Non-Current Assets	**1,089,054,762**	**1,097,500,049**
Property, Plant & Equipment	1,088,845,262	1,097,285,177
Intangible Assets	209,500	214,872
Current Assets	**1,053,536,193**	**1,031,557,506**
Inventories	375,929,376	389,201,629
Spare Parts & Supplies	26,075,427	27,569,583
Advances, Deposits & Pre-payments	253,387,849	217,469,219
Accounts Receivable	390,867,452	387,387,401
Cash & Bank Balances	7,276,089	9,929,674
Total	**2,142,590,955**	**2,129,057,555**
EQUITY & LIABILITY		
Shareholders' Equity	**1,643,844,272**	**1,631,717,942**
Share Capital	942,942,500	942,942,500
Revaluation Reserve	514,848,089	514,848,089
Retained Earnings	186,053,683	173,927,353
Non-Current Liabilities	**169,091,069**	**168,996,283**
Project Loan	106,232,789	106,232,789
Deferred Tax Liabilities	62,858,280	62,763,494
Current Liabilities	**329,655,614**	**328,343,330**
Short Term Loan	104,152,185	104,152,185
Sundry Creditors	3,247,683	4,080,654
Liabilities for Expenses	215,673,421	213,528,166
Others Payable	6,582,325	6,582,325
Total	**2,142,590,955**	**2,129,057,555**
Net Asset Value (NAV) per Share	**17.43**	**17.30**

Sd/- Chairman | Sd/- Director | Sd/- Managing Director | Sd/- Chief Financial Officer | Sd/- Company Secretary

Dated: Dhaka
14 November, 2016

Statement of Comprehensive Income (Un-Audited) for the period ended 30 September, 2016

Particulars	01-07-2016 to 30-09-2016 (3 months) Taka	01-07-2015 to 30-09-2015 (3 months) Taka
Turnover	**62,967,425**	**131,567,425**
Cost of Goods Sold	**(35,513,628)**	**(67,625,656)**
Gross Profit/(Loss)	**27,453,797**	**63,941,769**
Operating Expenses	**(10,344,234)**	**(18,242,280)**
Administrative Expenses	(3,256,784)	(4,654,360)
Selling & Distribution Expenses	(7,087,450)	(13,587,920)
Operating Income	**17,109,563**	**45,699,489**
Other Income	-	-
Financial Expenses	-	(3,724,719)
Net Profit/(Loss) before WPPF	**17,109,563**	**41,974,770**
Contribution to Workers' Profit Participation Fund	(814,741)	(1,998,799)
Net Profit/(Loss) before Tax	**16,294,822**	**39,975,971**
Income Tax Expenses	**(4,168,492)**	**(11,536,559)**
Current Tax	(4,073,706)	(10,993,392)
Deferred Tax	(94,786)	(543,167)
Net Profit/(Loss) after Tax	**12,126,330**	**28,439,412**
Earning per Share (EPS)	**0.13**	**0.30**
Number of Shares used to compute EPS	94,294,250	94,294,250

Sd/- Chairman | Sd/- Director | Sd/- Managing Director | Sd/- Chief Financial Officer | Sd/- Company Secretary

Dated: Dhaka
14 November, 2016

Statement of Changes in Equity (Un-Audited) for the period ended 30 September, 2016

Particulars	Share Capital	Revaluation Reserve	Retained Earnings	Total
Balance as on 01-07-2016	942,942,500	514,848,089	173,927,353	1,631,717,942
Addition during the period	-	-	12,126,330	12,126,330
Balance as on 30-09-2016	**942,942,500**	**514,848,089**	**186,053,683**	**1,643,844,272**

Sd/- Chairman | Sd/- Director | Sd/- Managing Director | Sd/- Chief Financial Officer | Sd/- Company Secretary

Dated: Dhaka
14 November, 2016

Statement of Cash Flows (Un-Audited) for the period ended 30 September, 2016

Particulars	01-07-2016 to 30-09-2016 Taka	01-07-2015 to 30-09-2015 Taka
Cash Flows from Operating Activities		
Collection from Customers	59,487,374	120,686,094
Payment to Supplier, Employees & Others	(58,575,176)	(118,905,415)
Net Cash Generated from Operating Activities	**912,198**	**1,780,679**
Cash Flows from Investing Activities		
Acquisition of Property, Plant & Equipment	(3,565,783)	(5,678,453)
Net Cash used in Investing Activities	**(3,565,783)**	**(5,678,453)**
Cash Flows from Financing Activities		
Cash dividend paid	-	8,156
Payment of IPO Proceeds	-	-
Project Loan	-	3,724,719
Short Term Loan from/(Repayment)	-	-
Bank Interest & Charges Paid	-	(3,724,719)
Net Cash Generated from Financing Activities	**-**	**8,156**
Net Cash Increase in Cash & Cash Equivalents	**(2,653,585)**	**(3,889,618)**
Cash & Cash Equivalents at the Beginning	**9,929,674**	**27,936,245**
Cash & Cash Equivalents at the End	**7,276,089**	**24,046,627**
Net Operating Cash Flows per Share (NOCFPS)	**0.01**	**0.02**

Sd/- Chairman | Sd/- Director | Sd/- Managing Director | Sd/- Chief Financial Officer | Sd/- Company Secretary

Dated: Dhaka
14 November, 2016

Notes to the Interim Financial Statements for the 1st Quarter ended 30 September, 2016

1.00 Reporting Entity

The Company was incorporated in 13 November, 1980 as a 'Private' Company limited by shares and registered with the Registrar of Joint Stock Companies & Firms of Bangladesh under the Companies Act, 1913 vide Registration No. C-8514(353). On 20 December, 2010 the Company registered itself as a Public Limited Company under the Companies, Act 1994. The Company is listed with both Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) at 22 July, 2013 and 15 July, 2013 respectively and trading of the share of the Company has been started from 14 August, 2013.

The registered and corporate office of the Company is located in its own premises at 2A/1, South-West Darus Salam Road (2nd Floor), Mirpur-1, Dhaka-1216 and its factory is situated in its own premises at 2A/1, South-West Darus Salam Road, Mirpur-1, Dhaka-

The principal activities of the Company throughout the year continued to be manufacturing and marketing of quality medicine.

2.00 Basis of Preparation of the interim Financial Statements:

These financial statements are the un-audited interim financial statements (here after 'the interim financial statements') of Central Pharmaceuticals Ltd., Companies incorporated in Bangladesh under the Companies Act, 1994 for the 1st quarter ended on 30 September, 2015 (here after 'the interim period'). They are prepared in accordance with the Bangladesh Accounting Standard (BAS-34) 'Interim Financial Reporting'. These financial statements should read in conjunction with the Annual Financial Statements as of 30 June, 2015, as they provided an update of previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, whic are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

Due to block account no interest hss been charged during the period.

Income Tax expense is recognized based upon the best estimate of the weighted average income tax expected for the reporting period.

The company has no reportable operating segments as per IFRS-8.

There is no significant event after the end of the interim period that has to be reflected in the financial statements for the interim period.

		30-09-2016 Taka	30-06-2016 Taka
3.00	**Project Loan-Long Term Portion:**		
	Janata Bank Ltd., Local Office Br., Dhaka A/C No. 010235035752	106,232,789	106,232,789
	Total	**106,232,789**	**106,232,789**
4.00	**Short Term Loan:**		
	Janata Bank Ltd., Local Office Br., Dhaka ICD Hypo-C.C 37004805	104,152,185	104,152,185
	Total	**104,152,185**	**104,152,185**

Note: The First Quarter Financial Statement (Un-audited) as of 30 September 2016 are Available in the website of the Company The address of the website is www.centralphl.com